- Home
- EQIX vs MRNA Comparison
EQIX vs MRNA Comparison
Compare EQIX & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQIX | MRNA |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.1B | 91.2B |
| IPO Year | 2000 | 2018 |
Fundamental Metrics
Financial Performance| Metric | EQIX | MRNA |
|---|---|---|
| Price | $1,061.74 | $273.39 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 35 | 23 |
| Target Price | ★ $1,234.88 | $149.37 |
| AVG Volume (30 Days) | 632.8K | ★ 14.5M |
| Earning Date | 10-28-2026 | 11-06-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | ★ 61.88 | 21.77 |
| EPS | ★ 13.96 | N/A |
| Revenue | $5,998,545,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $11.78 | $25.70 |
| Revenue Next Year | $11.30 | $6.28 |
| P/E Ratio | $72.68 | ★ N/A |
| Revenue Growth | ★ 7.85 | 4.29 |
| 52 Week Low | $720.62 | $22.28 |
| 52 Week High | $1,128.68 | $267.50 |
Technical Indicators
Market Signals| Indicator | EQIX | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 58.62 | 67.78 |
| Support Level | $1,046.20 | $45.39 |
| Resistance Level | $1,082.17 | N/A |
| Average True Range (ATR) | 36.49 | 23.11 |
| MACD | 7.10 | 3.04 |
| Stochastic Oscillator | 96.11 | 92.70 |
Price Performance
Historical ComparisonAbout EQIX Equinix Inc. REIT
Equinix is one of the leading providers of cloud- and carrier-neutral data centers, offering colocation and interconnection services to hyperscalers and businesses. Equinix operates 270 properties in 77 metropolitan areas across 36 countries, serving over 10,000 customers. About 70% of Equinix's revenue comes from renting physical space, which allows hyperscalers and other clients to store servers, data storage, and networking equipment. The other 30% of revenue is generated primarily through interconnection services (20%) and other managed services (10%).
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.